减肥药中国争夺战:降价、博弈与回归

中国医药创新促...
Mar 04

本文转载自深蓝观作者:李昀2026年,减重类药物市场在一致中产生了分歧。一方面,各大MNC和biotech还在对减重领域层层加码。在刚刚结束的JPM上,不少药企重申了对该方向将继续加大投入。而随着减重药进入2.0时代,全球药企正集体转向多靶点的管线布局。据医药魔方统计,仅在小分子领域,全球在研GLP-1药物共有88款,其中6款已进入Ⅲ期临床。另一方面,人们对减重药在实际治疗中的效果边界的认知,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10